Arnaud Lallouette, Executive Vice President Global Medical and Patient Affairs at Servier, shared a post on LinkedIn:
“At Servier, our mission is clear: to deliver transformative therapies to patients with significant unmet needs.
Today, we are taking another important step forward through a strategic partnership with IDEAYA Biosciences.
This licensing agreement aims to address an important medical need for patients living with a rare and aggressive eye cancer with limited treatment options remain limited.
We are ready to leverage our global oncology network and expertise with a simple ambition: to truly change the future for patients.”
More Posts Featuring Arnaud Lallouette at OncoDaily.